← Back to all signals
RESEARCH PAPER ANALYSIS

Investigator-initiated phase I trial of an oligonucleotide therapeutic targeting long noncoding RNA TUG 1 for recurrent glioblastoma.

AI interpretation is pending for this paper.

Open original publication →
PMID39948537
JournalBMC cancer
Publication Date2025-02-13
Ingested2026-08-02 12:03 AM
EXECUTIVE SUMMARY

What the AI sees

Not AI summarized yet.

WHY IT MATTERS

Research significance

Pending deeper interpretation.

ABSTRACT

Source abstract

BACKGROUND: Glioblastoma (GB) is the most common and aggressive primary malignant brain tumor in adults. To date, no effective treatment has been reported for recurrent GB (rGB). Long noncoding RNA taurine upregulated gene 1 (TUG1), which is highly expressed in GB, resolves the formation of R-loops, thereby maintaining tumor growth. TUG1-targeting antisense oligonucleotide (ASO) (TUG1ASO) is a nucleotide therapeutic with drug delivery system that targets TUG1, demonstrating efficacy against GB in mouse models. This multicenter, first-in-human, phase I trial aims to investigate the safety and maximum tolerated dose (MTD) of TUG1ASO. METHODS: This study will enroll patients aged 18-75 years with rGB following postoperative temozolomide plus radiation therapy. The primary endpoints will be the safety and tolerability of TUG1ASO and the MTD. The secondary endpoints will be the response rate, duration of response, progression-free survival, overall survival, and pharmacokinetics of TUG1ASO. Dose escalation will be performed utilizing a 3 + 3 design with four dose levels. Unless the discontinuation criteria are met, four cycles will be administered, with each cycle lasting 7 days. Administration of TUG1ASO will be possible until the discontinuation criteria are met. DISCUSSION: TUG1ASO is the first oligonucleotide therapeutic with drug delivery system targeting TUG1, expected to show an efficacy in rGB patients. In this first-in-human study, safety, tolerability and MTD of this new targeted therapy will be confirmed to find the recommended dose for the further clinical trial. This study may contribute to develop a new treatment option for rGB patients. TRIAL REGISTRATION: Japan Registry of Clinical Trials (jRCT) 2041230136, registration date May 17, 2024. REGISTRY: jRCT2041230136. REGISTRATION DATE: May 17, 2024. STUDY DATES: January 1, 2024, to present.

SUPPORTING PAPER SET

32 more papers to review

Ranked by current scoring engine
1 Chondroblastic osteosarcoma of the rib as a second primary malignancy following neuroblastoma: a case report. BMC surgery 70.2 2 Use of hair relaxers and hair dyes during pregnancy and breast tissue composition in mothers and adolescent daughters. Breast cancer research : BCR 72.2 3 Parental Perspectives on Using Large Language Model-Powered Chatbots in Rare Disease Care. NEJM AI 59.5 4 Low-Dose CT in the Age of Artificial Intelligence: Techniques, Evidence, and Clinical Impact. Tomography (Ann Arbor, Mich.) 55.62 5 Constructing Safety at Home: Parents' Experiences of the First Hospital-to-Home Transition in Childhood Cancer. Nursing reports (Pavia, Italy) 60.9 6 Sleep Disturbances and Health-Related Quality of Life in Paediatric Oncology: A Comparative Study with Non-Oncological Chronic Illness and Healthy Peers. Diseases (Basel, Switzerland) 64.0 7 Subungual Exostoses as an Infrequent Cause of Pain and Nail Plate Deformities of the First Toe: A Retrospective Cohort Study. Journal of the American Podiatric Medical Association 69.0 8 Association Between Internet Access and Human Papillomavirus (HPV) Vaccination Coverage in Brazilian Municipalities: An Ecological Study. Vaccines 38.5 9 The Same, but Different: Shared Hallmarks and Divergent Drivers in Adult, Pediatric and Canine Glioma. Current oncology (Toronto, Ont.) 56.0 10 Clinical and Dermoscopic Features of Subungual Hemorrhage: A Retrospective Study of 420 Cases. Skin research and technology : official journal of International Society for Bioengineering and the Skin (ISBS) [and] International Society for Digital Imaging of Skin (ISDIS) [and] International Society for Skin Imaging (ISSI) 68.0 11 RANK/RANKL/OPG Axis Expression and Response to Anti-RANKL Therapy in Gnathic Giant Cell Lesions: A Systematic Review and Meta-Analysis. Diseases (Basel, Switzerland) 79.26 12 Pleural and Thoracic Air-Leak Complications After Hematopoietic Cell Transplantation: Diagnosis and Procedural Management. Advances in respiratory medicine 61.4 13 Characterizing the Novel CRP, IP-10, and TRAIL Host-Response Protein Signature in Pediatric Kingella kingae Infections-A Retrospective Cohort Study. Pediatric reports 66.62 14 Adaptive Decision-Level Fusion for Osteosarcoma Classification Using Unpaired X-Ray and Histopathology Data. Journal of imaging 56.0 15 Secondary Intracranial Hypertension During ATRA/ATO Therapy in High-Risk Acute Promyelocytic Leukemia: A Case Report and Practical Management Framework. Current oncology (Toronto, Ont.) 61.04 16 Associations Between Cereal-Based Food Consumption and Urinary Mycotoxin Biomarkers in a Hungarian Population. Toxins 39.55 17 Temporal Dynamics of Emerging Cardiovascular Biomarkers in the Early Phase After Acute ST-Segment Elevation Myocardial Infarction: A Prospective Single-Center Pilot Study. Cells 62.85 18 Safety and Efficacy of Photon Re-Irradiation with Whole-Brain Radiotherapy or Craniospinal Irradiation for Recurrent Pediatric Central Nervous System Malignancies. Current oncology (Toronto, Ont.) 72.64 19 Intestinal Mature B-Cell Non-Hodgkin Lymphoma Presenting as an Acute Surgical Abdomen in Children: A Case Series. Pediatric reports 55.4 20 Characteristics and Resistance Patterns of Gram-Negative Bacterial Isolates to Third-Generation Cephalosporins in Oncology ICU Patients: A Ten-Year Retrospective Analysis. Pathogens (Basel, Switzerland) 63.9 21 Depression and Anxiety Among Adolescents with Cancer: A Saudi Cross-Sectional Study. Pediatric reports 64.4 22 Fine particulate matter and minimal residual disease in childhood acute lymphoblastic leukemia from the REDIAL consortium. JNCI cancer spectrum 70.3 23 Cancer incidence among people with intellectual disability: a nationwide population-based cohort study in Denmark. Disability and health journal 57.5 24 Robot-assisted laparoscopic resection of paediatric retroperitoneal neurogenic tumours: a retrospective single-centre study of 117 patients. Journal of robotic surgery 67.0 25 Age, tumor size, and therapy timing are associated with survival in primary spinal Ewing sarcoma: a nationwide analysis. European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society 72.96 26 The Current State of Primary Clinical Spine Disease Research in Sub-Saharan Africa - A Scoping Review. Global spine journal 56.0 27 Vulvar Crohn's disease in children: Diagnostic challenges and therapeutic implications from a literature review. Journal of pediatric gastroenterology and nutrition 67.44 28 Identification and characterization of a novel distinct Pineal Neoplasm with Neuroendocrine and Epithelial Differentiation (PINNED). Acta neuropathologica 52.9 29 Sexual inactivity in young adult survivors of childhood cancer: a Project REACH study. Journal of cancer survivorship : research and practice 75.8 30 Secondary minimally differentiated acute leukemia with plasmacytoid dendritic cell differentiation (pDC-AML) following chemoradiotherapy for Ewing sarcoma in a child: biallelic EZH2 inactivation. Leukemia & lymphoma 61.94 31 Family-based treatment for intergenerational diseases. Health psychology : official journal of the Division of Health Psychology, American Psychological Association 62.74 32 Evaluating the impact of intraoperative neuromonitoring on neurological outcomes and extent of resection in pediatric supratentorial brain tumor surgery: a systematic review and meta-analysis. Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia 73.0
PATIENT-FRIENDLY SUMMARY

Investigator-initiated phase I trial of an oligonucleotide therapeutic targeting long noncoding RNA TUG 1 for recurrent glioblastoma.

For education only—not personal medical advice.

Before you continue

AI-assisted research information

Neurocompute uses AI to summarize scientific papers, interpret research signals, and suggest relevant reference links. AI-generated content can be incomplete, misleading, or wrong, and generated links may be irrelevant or unavailable.

Our reviewed outputs have performed strongly to date, but past accuracy is not a guarantee. Verify summaries, scores, claims, and links against the original publication before relying on them.

This platform is for research and education only. It does not provide medical advice, diagnosis, treatment recommendations, or clinical guidance.

Pediatric cancer research intelligence graphic
PEDIATRIC CANCER VISUAL SYSTEM

Open the Research Intelligence Map

Explore the active pediatric oncology analysis view.

Expand Intelligence View →
Full Pediatric cancer research intelligence graphic